Dyne Therapeutics Inc. (DYN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
NEW YORK, NY / ACCESSWIRE / October 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ:DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Related Infractions
LOS ANGELES, CA / ACCESSWIRE / October 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ:DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Violating Securities Laws
LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Impacted Shareholders Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
